

**Completed Phase II Clinical Trials with ACC Patients**  
**(Updated August 2012)**

Compound	Target(s)	Institution	ACC Patients	Objective Response	Stable Disease	Clinical Benefit	Progression Required?	Publication Year	Link
<a href="#">Sunitinib</a> (Sutent)	PDGFR, VEGFR, CKIT, RET	Princess Margaret Hospital	13	0%	85%	62%	Yes	2011	<a href="#">View</a>
<a href="#">Cetuximab</a> (Erbixux)	EGFR	Istituto Nazionale dei Tumori	23	0%	87%	52%		2009	<a href="#">View</a>
<a href="#">Gemcitabine</a> & <a href="#">Cisplatin</a>	Chemotherapy	NCI Canada	10	20%	NA			2009	<a href="#">View</a>
<a href="#">Gemcitabine</a>	Chemotherapy	Radboud University Nijmegen	21	0%	52%	48%		2008	<a href="#">View</a>
<a href="#">Lapatinib</a> (Tykerb)	EGFR, HER2	Princess Margaret Hospital	19	0%	79%	47%	Yes	2007	<a href="#">View</a>
<a href="#">Bortezomib</a> (Velcade)	Proteasome, NFKB	University of Pittsburgh/ECOG	25	0%	64%		Yes	2006	<a href="#">View</a>
<a href="#">Gefitinib</a> (Iressa)	EGFR	MD Anderson	19	0%	68%		Yes	2005	<a href="#">View</a>
<a href="#">Imatinib</a> & <a href="#">Cisplatin</a>	ABL, CKIT, PDGFR	Christie Hospital NHS Trust	28	11%	68%		Yes	2011	<a href="#">View</a>
<a href="#">Imatinib</a> (Gleevec)	ABL, CKIT, PDGFR	Tel Aviv University	10	0%	70%			2007	<a href="#">View</a>
<a href="#">Imatinib</a> (Gleevec)	ABL, CKIT, PDGFR	Princess Margaret Hospital	15	0%	56%			2005	<a href="#">View</a>
<a href="#">Paclitaxel</a>	Chemotherapy	LSU/ECOG	13	0%	54%			2006	<a href="#">View</a>
<a href="#">Paclitaxel</a> & <a href="#">Carboplatin</a>	Chemotherapy	University of Torino	10	20%	NA		Yes	2000	<a href="#">View</a>
<a href="#">Vinorelbine</a> & <a href="#">Cisplatin</a>	Chemotherapy	University of Torino	9	44%	NA		Yes	2001	<a href="#">View</a>
<a href="#">Vinorelbine</a>	Chemotherapy	University of Torino	13	15%	NA		Yes	2001	<a href="#">View</a>
<a href="#">Epirubicin</a>	Chemotherapy	Free University Hospital (NL)	20	10%	50%		Yes	1993	<a href="#">View</a>
<a href="#">Cisplatin</a> & 5-FU	Chemotherapy	Royal Marsden NHS Trust	11	0%	55%			1997	<a href="#">View</a>
<a href="#">Cisplatin</a> & <a href="#">Doxorubicin</a> & <a href="#">Cyclophosphamide</a>	Chemotherapy	Istituto Nazionale dei Tumori	12	25%	42%		Yes	1996	<a href="#">View</a>
<a href="#">Cisplatin</a> & <a href="#">Doxorubicin</a> & <a href="#">Bleomycin</a>	Chemotherapy	Radboud University Nijmegen	9	33%	55%			1992	<a href="#">View</a>
<a href="#">Cisplatin</a>	Chemotherapy	Radboud University Nijmegen	10	0%	50%			1992	<a href="#">View</a>
<a href="#">Cisplatin</a>	Chemotherapy	Istituto Nazionale dei Tumori	13	15%	46%			1991	<a href="#">View</a>
<a href="#">Mitoxantrone</a>	Chemotherapy	Rotterdam Cancer Institute	32	12%	69%			1996	<a href="#">View</a>
<a href="#">Mitoxantrone</a>	Chemotherapy	Johns Hopkins	18	6%	67%			1990	<a href="#">View</a>